A historic breakthrough in pancreatic cancer treatment! FDA approves RevMed's targeted new drug, with sales expected to exceed $9 billion by 2032.

Revolution Medicines (RevMed)'s new pancreatic cancer drug, daraxonrasib, has received approval from the U.S. Food and Drug Administration (FDA) for market launch, making it the first targeted therapy addressing the key molecular pathogenic mechanism of this disease, marking one of the most significant breakthroughs in pancreatic cancer treatment in years.

According to data disclosed by the FDA, in a final-stage clinical trial, daraxonrasib extended the median survival for patients with aggressive pancreatic cancer to 13.2 months, nearly doubling the 6.7 months seen in those receiving chemotherapy (the current standard of care).

FDA Acting Director Kyle Diamantas stated, "Today's approval provides a crucial new option for patients facing this extremely aggressive and historically difficult-to-treat cancer."

The drug will be launched under the trade name Rasonque, with an annual list price exceeding $475,000. Approved indications include metastatic pancreatic cancer patients who have received at least one line of systemic therapy or are unsuitable for such treatments.

After the announcement, RevMed's share price rose, up 2.5% intraday at the time of reporting. Year-to-date, the stock has more than doubled, and the company's market value has surpassed $45 billion. Wall Street analysts predict that sales of the drug could exceed $9 billion by 2032.

The core value of daraxonrasib lies in its unique mechanism of action.

RAS is a protein closely linked to tumor growth and is mutated in the vast majority of pancreatic cancer cases. However, for many years, researchers have been unable to develop drugs that can broadly and effectively target its various variants. RevMed has adopted an innovative "molecular glue" technology, which wraps and inhibits this dangerous protein, enabling effective targeting of RAS.

Memorial Sloan Kettering Cancer Center oncologist and lead author of the final-stage trial, Eileen O'Reilly, stated in an interview before the FDA announcement, "This is a tremendous advance."

As a once-daily oral tablet, daraxonrasib also has the potential to improve the patient treatment experience—patients can take the drug at home without frequent trips to infusion centers. For those living with incurable diseases, this means more time with their families.

RevMed is currently advancing clinical trials to explore the feasibility of using the drug in earlier stages of the disease.

Pancreatic cancer has an extremely high mortality rate, with a five-year survival rate of just 13%. According to the American Cancer Society, over 67,000 people will be diagnosed with pancreatic cancer this year, and more than 52,000 will die from the disease.

Market attention for the drug was already high prior to formal approval. In April of this year, former U.S. Senator Ben Sasse publicly revealed his stage IV pancreatic cancer diagnosis and reported being treated with the drug, which brought significant attention to daraxonrasib. RevMed's share price has more than doubled since April.

Demand from patients and families was intense during the approval process. In May, the FDA allowed RevMed to launch a special expanded access program so that patients ineligible for clinical trials could still receive the drug. By early August, RevMed stated it had provided the drug to over 2,000 patients through this program.

In terms of regulatory procedures, daraxonrasib also received "ultra-fast review" status under the FDA’s newly established voucher program, which is designed to accelerate the approval process for promising drugs.

The FDA stated that this review was completed 6.5 months ahead of the statutory deadline.

FDA-approved indications also cover patient groups unsuitable for systemic therapy. The FDA noted that known side effects include rash and mouth ulcers.